Increased Soluble CMG2 Serum Protein Concentration is Associated with the Progression of Prostate Carcinoma.
CMG2
prognosis
prostate cancer
serum biomarker
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
26 Jul 2019
26 Jul 2019
Historique:
received:
26
06
2019
revised:
24
07
2019
accepted:
25
07
2019
entrez:
31
7
2019
pubmed:
31
7
2019
medline:
31
7
2019
Statut:
epublish
Résumé
Prostate carcinoma (PCa) is one of the leading causes of cancer-related death in males, but biomarkers for the prognosis are rare. Capillary morphogenesis gene 2 (CMG2) is a modulator of extracellular matrix remodeling during angiogenesis. Four isoforms of CMG2 have been described so far, one secreted in the serum as soluble CMG2 (sCMG2). The aim of this study was to evaluate the sCMG2 serum concentrations in 179 PCa patients and 163 age-matched control subjects by ELISA and correlate it to clinical and demographic parameters. We observed that sCMG2 concentration is increased in the serum of PCa patients with metastases, while no significant differences in the concentrations were detected between the control subjects and patients with localized PCa. Furthermore, elevated sCMG2 concentrations were significantly associated with the highest T stage. Increased sCMG2 serum concentrations tended to be associated with a worsened overall and disease-specific survival of the PCa patients. In conclusion, sCMG2 may be an interesting additive biomarker for the prediction of the progression of PCa and the patients' outcome.
Identifiants
pubmed: 31357506
pii: cancers11081059
doi: 10.3390/cancers11081059
pmc: PMC6721319
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Int J Oncol. 1999 Mar;14(3):535-41
pubmed: 10024688
Cancer Res. 1999 Dec 1;59(23):5975-9
pubmed: 10606244
J Cell Sci. 2001 Aug;114(Pt 15):2755-73
pubmed: 11683410
Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5170-4
pubmed: 12700348
Oncogene. 2010 Feb 11;29(6):789-801
pubmed: 19901963
Front Biosci (Landmark Ed). 2011 Jan 01;16:1574-88
pubmed: 21196249
Int J Cancer. 2012 Feb 1;130(3):611-21
pubmed: 21400514
PLoS One. 2011;6(6):e20646
pubmed: 21674060
Int J Cancer. 2012 Aug 1;131(3):652-61
pubmed: 22052531
Histopathology. 2012 Jan;60(1):87-117
pubmed: 22212080
Cell Cycle. 2012 Jun 15;11(12):2253-9
pubmed: 22617387
Bioorg Med Chem Lett. 2012 Sep 15;22(18):5885-8
pubmed: 22910038
J Med Chem. 2013 Mar 14;56(5):1940-5
pubmed: 23394144
J Cancer Res Clin Oncol. 2014 Jun;140(6):957-67
pubmed: 24667935
Intern Med J. 2014 May;44(5):433-40
pubmed: 24816306
Biochem Biophys Res Commun. 2014 Sep 12;452(1):186-90
pubmed: 24924630
Oncol Lett. 2014 Jun;7(6):2149-2153
pubmed: 24932305
Int J Oncol. 2014 Oct;45(4):1565-73
pubmed: 24993339
DNA Cell Biol. 2015 Mar;34(3):189-200
pubmed: 25521481
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Int J Cancer. 2015 Sep 15;137(6):1406-16
pubmed: 25754273
Expert Rev Mol Diagn. 2015;15(12):1567-76
pubmed: 26548550
Biomark Med. 2016;10(2):209-16
pubmed: 26764285
Toxins (Basel). 2016 Jan 20;8(1):null
pubmed: 26805881
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Urol Oncol. 2016 Nov;34(11):490-501
pubmed: 27771279
Nat Commun. 2017 Jun 12;8:15861
pubmed: 28604699
Int J Mol Sci. 2017 Dec 07;18(12):null
pubmed: 29215551
J Pathol. 2018 Jun;245(2):160-171
pubmed: 29473166
Oncogene. 2018 Jul;37(29):3953-3966
pubmed: 29662192
Adv Anat Pathol. 2018 Sep;25(5):293-303
pubmed: 29727322
Medicine (Baltimore). 2018 Oct;97(42):e12806
pubmed: 30334974
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Prostate Cancer Prostatic Dis. 2019 Sep;22(3):438-445
pubmed: 30664734
J Med Chem. 2019 Apr 25;62(8):3958-3970
pubmed: 30964669
Folia Neuropathol. 2019;57(1):6-15
pubmed: 31038183